M E Torregrosa-Quesada1, A García-Martínez2, A Sánchez-Barbie3, S Silva-Ortega4, R Cámara5, C Fajardo6, C Lamas7, I Aranda4, A Pico8. 1. Department of Biochemical Analysis, Alicante General University Hospital-Institute for Health and Biomedical Research (ISABIAL), 03010, Alicante, Spain. 2. Research Laboratory, Alicante General University Hospital-Institute for Health and Biomedical Research (ISABIAL). CIBER Rare Diseases, 03010, Alicante, Spain. 3. Centro de Investigación Operacional (CIO), Miguel Hernández University, 03010, Alicante, Spain. 4. Department of Pathology, Alicante General University Hospital-Institute for Health and Biomedical Research (ISABIAL), 03010, Alicante, Spain. 5. Department of Endocrinology and Nutrition, Polytechnic University Hospital La Fe, 46026, Valencia, Spain. 6. Department of Endocrinology and Nutrition, Hospital La Ribera, Alzira, 46600, Valencia, Spain. 7. Department of Endocrinology and Nutrition, Albacete General University Hospital, 02006, Albacete, Spain. 8. Department of Endocrinology and Nutrition, Alicante General University Hospital. Institute for Health and Biomedical Research (ISABIAL). University Miguel Hernandez. CIBER Rare Diseases, 03010, Alicante, Spain. antonio.pico@umh.es.
Abstract
INTRODUCTION: Tumors of the anterior pituitary gland (PTs) are mostly benign tumors with a low prevalence, which has nevertheless increased with advances in brain radiology techniques. Nearly half of PTs are not associated with a clinical endocrine syndrome. These tumors have been indistinctly named non-functioning pituitary adenomas (NFPAs) or silent pituitary tumors (SPTs) and the mechanisms of silencing are not fully known. AIM: To study the frequency and characterize the silent variant of PTs in a large local series, and to assess their pituitary adenohypophyseal gene expression. METHODS: This observational, cross-sectional study was performed in a Pituitary Tumor Center of Excellence and involved 268 PTs. After identifying the different subtypes according to the immunohistochemical (IHC) expression of adenohypophyseal hormones, we studied their gene expression by RT-qPCR. RESULTS: We found that silent tumors were larger and more invasive, but not more proliferative than their functional counterparts. The RT-qPCR complements the IHC typification of PTs, reducing the proportion of null-cell subtype. Finally, some silent PT subtype variants showed lower specific adenohypophyseal hormone gene expression than their functional counterparts, which may contribute to the absence of endocrine manifestations. CONCLUSIONS: This paper highlights the importance of identifying the silent variant of the PTs subtypes. As expected, silent tumors were larger and more invasive than their functioning counterparts. However, there was no difference in the proliferation activity between them. Finally, the lower specific gene expression in the silent than in the functioning counterparts of some PTs subtypes gives insights into the silencing mechanisms of PTs.
INTRODUCTION: Tumors of the anterior pituitary gland (PTs) are mostly benign tumors with a low prevalence, which has nevertheless increased with advances in brain radiology techniques. Nearly half of PTs are not associated with a clinical endocrine syndrome. These tumors have been indistinctly named non-functioning pituitary adenomas (NFPAs) or silent pituitary tumors (SPTs) and the mechanisms of silencing are not fully known. AIM: To study the frequency and characterize the silent variant of PTs in a large local series, and to assess their pituitary adenohypophyseal gene expression. METHODS: This observational, cross-sectional study was performed in a Pituitary Tumor Center of Excellence and involved 268 PTs. After identifying the different subtypes according to the immunohistochemical (IHC) expression of adenohypophyseal hormones, we studied their gene expression by RT-qPCR. RESULTS: We found that silent tumors were larger and more invasive, but not more proliferative than their functional counterparts. The RT-qPCR complements the IHC typification of PTs, reducing the proportion of null-cell subtype. Finally, some silent PT subtype variants showed lower specific adenohypophyseal hormone gene expression than their functional counterparts, which may contribute to the absence of endocrine manifestations. CONCLUSIONS: This paper highlights the importance of identifying the silent variant of the PTs subtypes. As expected, silent tumors were larger and more invasive than their functioning counterparts. However, there was no difference in the proliferation activity between them. Finally, the lower specific gene expression in the silent than in the functioning counterparts of some PTs subtypes gives insights into the silencing mechanisms of PTs.
Authors: Tomas Thor Agustsson; Tinna Baldvinsdottir; Jon G Jonasson; Elinborg Olafsdottir; Valgerdur Steinthorsdottir; Gunnar Sigurdsson; Arni V Thorsson; Paul V Carroll; Márta Korbonits; Rafn Benediktsson Journal: Eur J Endocrinol Date: 2015-11 Impact factor: 6.664
Authors: B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young Journal: Neurosurgery Date: 2000-09 Impact factor: 4.654
Authors: Axel Tjörnstrand; Kerstin Gunnarsson; Max Evert; Erik Holmberg; Oskar Ragnarsson; Thord Rosén; Helena Filipsson Nyström Journal: Eur J Endocrinol Date: 2014-08-01 Impact factor: 6.664
Authors: Zhiyuan Xu; Scott Ellis; Cheng-Chia Lee; Robert M Starke; David Schlesinger; Mary Lee Vance; M Beatriz Lopes; Jason Sheehan Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-09 Impact factor: 7.038
Authors: Laura Sanchez-Tejada; Ruth Sanchez-Ortiga; Cristina Lamas; Rosa Camara; Pedro Riesgo; Carmen Fajardo; Francisco Ignacio Aranda; Antonio Pico Journal: PLoS One Date: 2017-07-10 Impact factor: 3.240
Authors: C Campana; F Nista; L Castelletti; M Caputo; E Lavezzi; P Marzullo; A Ferrero; G Gaggero; F R Canevari; D C Rossi; G Zona; A Lania; D Ferone; F Gatto Journal: J Endocrinol Invest Date: 2022-02-11 Impact factor: 5.467